MedMira is 1 of 21 Companies Targeted for Global Success Only Canadian Company to Make Prestigious IW21 List HALIFAX, Jan. 5 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it was named to the InnovationWORLD 21, a prestigious list of twenty-one companies poised for significant growth. InnovationWORLD, a prominent US based publisher who is a key source of business intelligence on growing companies, placed MedMira on its list of the top 21 companies out of over 240 reviewed in 2004. The IW21 list is comprised of companies that InnovationWORLD finds to have unique products with excellent operational capabilities and financial management that give them a leading edge against other companies. Says MedMira chairman and CEO, Stephen Sham "We are very encouraged and pleased to be the only Canadian company recognized in this way by this high-profile business intelligence publication." Continues Mr. Sham, "Our excellent operational growth in 2004, combined with continually increasing numbers of solid distribution agreements globally and escalating U.S. market penetration proves we are on track to make solid gains in 2005. This independent recognition by InnovationWORLD is a testament to the progress that we have made to date and of our future growth potential." InnovationWORLD interviews and researches hundreds of growth-stage businesses each year in the United States and Canada to gain an understanding of their products, global expansion plans, operational and financial strategies. The IW21 list, including such companies as Vonage, Taser International and Falcon WaterFree, recognizes businesses in biotechnology, telecommunications, pharmaceuticals, and other advanced technologies. During the 2004 calendar year, MedMira made gains in the U.S. hospital market, steadily increased revenues, opened new markets in Africa, Middle East and Caribbean, achieved repeat sales from established distributors and successfully positioned its MiraWell(TM) Rapid HIV Test as the number one rapid HIV test in China in an independent National CDC study. MedMira continues to make steady gains through a strict sales and marketing regimen and tight financial and operational management. MedMira is the only Canadian biotechnology company granted approvals from Health Canada, United States FDA and China SFDA for its rapid HIV tests. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow-though rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com/. MedMira's Reveal(TM) and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. DATASOURCE: MedMira Inc. CONTACT: Media : Investor Relations, Dr. James Smith, (902) 450-1588, e-mail:

Copyright